Reuters reports on a promising innovation in cancer therapy, which has yielded 100% survival rates among cancer-stricken mice.
The therapy, published in the latest Nature Biotechnology journal, sees mini-cells called EDVs (EnGenelC Delivery Vehicle) attach and enter the cancer cell.
The first wave of mini-cells release ribonucleic acid molecules, called siRNA, which switch off the production of proteins that make the cancer cell resistant to chemotherapy.
A second wave of EDV cells is then accepted by the cancer cell and releases chemotherapy drugs, killing the cancer cell.
"The beauty is that our EDVs operate like 'Trojan Horses.' They arrive at the gates of the affected cells and are always allowed in," said [Dr. Jennifer] MacDiarmid.
"We are playing the rogue cells at their own game. They switch-on the gene to produce the protein to resist drugs, and we are switching-off the gene which, in turn, enables the drugs to enter." ...
The Nature report said the mini-cells were "well tolerated with no adverse side effects or deaths in any of the actively treated animals, despite repeated dosing."
Human trials will start next week in Australia. Could this be the beginnng of the end for cancer?